<DOC>
	<DOCNO>NCT02172885</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness five infusion characterize HLA-identical MSC non immunosuppressed child Osteogenesis Imperfecta ( OI ) .</brief_summary>
	<brief_title>Mesenchymal Stem Cell Based Therapy Treatment Osteogenesis Imperfecta</brief_title>
	<detailed_description>The principal aim trial ass safety non-mutated HLA-identical Mesenchymal stem cell ( MSC ) transplantation OI pediatric patient irrespective treatment biphosphonates . Since MSC inherently non-immunogenic elicit proliferation allogeneic lymphocyte ( co-culture experiment ) , cell therapy base HLA-identical histocompatible ( least 5 share 6 HLA antigen ) allogenic MSC may accomplish without subject patient immunosuppressor treatment . Adverse secondary effect due immunosuppressor treatment avoid use strategy thus patient may benefit two cellular infusion . The patient follow 2 year post fifth last MSC infusion .</detailed_description>
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<criteria>Patient age : old 6 month young 12 year old . Patients molecular confirmation mutation either COL1A1 COL1A2 gene associate OI ( type III ) . Patients HLA identical ( share least 5/6 antigen ) sibling willing donate bone marrowMSCs . All patient fulfil inclusion criterion regardless whether undergo biphosphonate treatment . Patients whose parent legal guardian willing sign consent form participate clinical trial . Patient age : old 12 year old Patients lack confirmation mutation either COL1A1 COL1A2 gene associate severe deform OI ( type III ) . Other pathological subtypes OI . Patients lack HLA identical ( share least 5/6 antigen ) sibling willing donate bone marrowMSCs . Immunodeficiencies malignancy . Participation clinical trial . Any medical psychiatric condition researcher´s opinion could affect patient´s ability complete trial hamper participation trial . Patients whose parent legal guardian sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mesenchymal stem cell base therapy</keyword>
	<keyword>cell infusion</keyword>
</DOC>